ArtNr |
ABC-AP6190a-ev-80ul |
Hersteller |
Abcepta
|
Menge |
80 ul |
Kategorie |
|
Typ |
Antibody Polyclonal |
Applikationen |
Western Blot, Immunohistochemistry |
Specific against |
other |
Host |
Rabbit |
Isotype |
Ig |
ECLASS 10.1 |
32160702 |
ECLASS 11.0 |
32160702 |
UNSPSC |
12352203 |
Alias |
Protein AF-9, ALL1-fused gene from chromosome 9 protein, Myeloid/lymphoid or mixed-lineage leukemia translocated to chromosome 3 protein, YEATS domain-containing protein 3, MLLT3, AF9, YEATS3 |
Lieferbar |
|
Primary Accession |
P42568 |
Other Accession |
A2AM29 |
Antigen Type |
Synthetic Peptide |
Bio Background |
The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t(9; 11)(p22; q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified; BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed. |
Bio References |
Iida, S., et al., Oncogene 8(11):3085-3092 (1993). Nakamura, T., et al., Proc. Natl. Acad. Sci. U.S.A. 90(10):4631-4635 (1993). Strissel, P. L., et al., Hum. Molec. Genet. 9: 1671-1679 (2000). |
Gene ID |
4300 |
Gene Name |
MLLT3 {ECO:0000303|PubMed:16001262, ECO:0000312|HGNC:HGNC:7136} |
Reactivity |
H |
Predicted |
M |
Calculated MW |
63351 |
Antigen Region |
471-502 |
Antigen Source |
HUMAN |
Target/Specificity |
This AF9 (MLLT3) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 471-502 amino acids from the C-terminal region of human AF9 (MLLT3). |
NCBI Accession |
NP_004520.2 |
Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.
Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.